Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.33 |
| ▸ | FAAH | O00519 | 5/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 2/20 | 0.32 |
| ▸ | THPO | P40225 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163868 | 0.73 | MGLL (0.34) | MGLLFAAHNPSR1MAPK1ALDH1A1 | |
| SCHEMBL3468977 | 0.71 | POLB (0.31) | LMNA | |
| SCHEMBL19057261 | 0.70 | MGLL (0.46) | MGLLFAAHNPSR1MAPK1ALDH1A1 | |
| SCHEMBL1163645 | 0.70 | MGLL (0.52) | MGLLFAAHNPSR1MAPK1ALDH1A1 | |
| SCHEMBL4340966 | 0.66 | — | — | |
| SCHEMBL83079 | 0.64 | MGLL (0.42) | MGLLFAAHNPSR1MAPK1ALDH1A1 | |
| SCHEMBL709406 | 0.64 | MGLL (0.42) | MGLLFAAHNPSR1MAPK1ALDH1A1 | |
| SCHEMBL30710 | 0.62 | MGLL (0.62) | MGLLFAAHNPSR1MAPK1ALDH1A1 | |
| SCHEMBL11749637 | 0.60 | ALDH1A1 (0.47) | MGLLFAAHMAPK1ALDH1A1LMNA | |
| SCHEMBL29760770 | 0.60 | MGLL (0.59) | MGLLFAAHNPSR1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022018667-A1 | COMBINATION THERAPIES USING CDK2 AND CDC25A INHIBITORS | PFIZER INC. (US) | 2022-01-27 | — | — | WO | claimed |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4536363-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119790053-A | Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors | 霖康疗法公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119053595-A | Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors | 尼坎治疗公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2022018667-A1 | COMBINATION THERAPIES USING CDK2 AND CDC25A INHIBITORS | PFIZER INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | MGLL 4316/4885FAAH 4302/4885NPSR1 4299/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | MGLL 4316/4885FAAH 4302/4885NPSR1 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.